Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(17/week)
India
(8/week)
Singapore
(2/week)
China, P. R.
(1/week)
Philippines
(1/week)
View all
(31/week)
News
United States
(1121/week)
Manufacturing
(562/week)
Technology
(1133/week)
Energy
(412/week)
Other Manufacturing
(384/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Durvalumab
Sep 29, 2018
First Patient Dosed in a Phase III Trial of Anti-PD-1 Antibody Sintilimab as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer
Sep 06, 2018
Quantum Leap Healthcare Collaborative Announces AstraZeneca's Olaparib And Durvalumab For The I-SPY 2 Trial For Breast Cancer
Aug 07, 2018
Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update
Jun 03, 2018
Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer
May 09, 2018
First and Only Immuno-Oncology Treatment, Imfinzi® (durvalumab), for Stage III, Unresectable Non-Small Cell Lung Cancer Now Approved in Canada
Apr 24, 2018
Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials
Mar 15, 2018
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer
Feb 16, 2018
US FDA APPROVES IMFINZI® (DURVALUMAB) FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER
Feb 16, 2018
FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing
Feb 13, 2018
Phase II trial demonstrates activity of durvalumab in patients with recurrent or metastatic head and neck cancer
Feb 01, 2018
Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
Jan 29, 2018
SillaJen Announces First Patient Enrolled in the NCI-Sponsored Trial Evaluating Combination Therapy in Colorectal Cancer with SillaJen's Pexa-Vec Oncolytic Immunotherapy
Nov 28, 2017
Checkpoint Inhibitors for Treating Cancer Market Report 2017-2027
Nov 13, 2017
Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs
Nov 09, 2017
NSCLC: KOL Insight 2017
Nov 06, 2017
Health Canada Approves IMFINZI® (durvalumab) for Previously Treated Patients with Advanced Bladder Cancer
Nov 01, 2017
Checkpoint Inhibitors for Treating Cancer Market Report 2017-2027
Oct 12, 2017
Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients
Aug 31, 2017
TapImmune Provides Second Quarter 2017 Corporate and Clinical Update
Jun 01, 2017
Parker Institute for Cancer Immunotherapy Scientists to Present Research at ASCO 2017 on IDO Pathway Inhibitors, Novel CAR-Ts and the Microbiome's Potential in Immunotherapy
‹‹
Page 2
Latest News
Sep 1, 2024
Insta Max 20K Puffs Vape: The Future of Vaping Has Arrived
Sep 1, 2024
Kodiak Gas Services Announces 2023 Schedule K-3 Investor Tax Packages for CSI Compressco LP Are Available...
Aug 31, 2024
Suzano completes purchase of 15% stake in Lenzing AG
Aug 31, 2024
Noble Corporation plc announces changes to its share capital including share repurchases for the month of...
Aug 31, 2024
FP Markets Wins Double at FMPS 2024
Aug 31, 2024
Kenya airport workers' union delays strike again
Aug 31, 2024
CGTN: China, Africa set to embrace closer economic, trade ties at FOCAC
Aug 31, 2024
United Imaging Healthcare Reports nearly 30% YoY Growth in Overseas Market Revenue, H1 Revenue Reaches 5.33...
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
View All Events